Comparative Pharmacology
Head-to-head clinical analysis: ESIDRIX versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESIDRIX versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50.
ESIDRIX vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle via mechanisms involving interference with calcium ion movement and possibly nitric oxide release. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
1 tablet (hydralazine 50 mg/hydrochlorothiazide 50 mg) orally twice daily, maximum 2 tablets daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
Hydralazine: 2-8 hours (acetylator phenotype dependent; slow acetylators up to 8h, fast acetylators 1-2h). Hydrochlorothiazide: 6-15 hours (mean 10h).
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Hydralazine: 80% renal (mainly as metabolites, 1-2% unchanged), 10% fecal. Hydrochlorothiazide: >95% renal (unchanged) via organic anion transporters.
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic